MLTX logo

MLTX
MoonLake Immunotherapeutics

5,759
Mkt Cap
$1.17B
Volume
682,635.00
52W High
$62.75
52W Low
$5.95
PE Ratio
-4.61
MLTX Fundamentals
Price
$16.27
Prev Close
$16.68
Open
$16.68
50D MA
$16.85
Beta
0.58
Avg. Volume
1.42M
EPS (Annual)
-$3.53
P/B
3.81
Rev/Employee
$0.00
$531.37
Loading...
Loading...
News
all
press releases
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating
Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and set a $40.00 price target on the stock in a report on Thursday...
MarketBeat·3d ago
News Placeholder
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX
Caitong International Asset Management Co. Ltd increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 22,387.5% in the third quarter, according to its most recent 13F...
MarketBeat·4d ago
News Placeholder
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Key PointsCormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average...
Nasdaq News: Markets·5d ago
News Placeholder
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX
Boxer Capital Management LLC bought a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·7d ago
News Placeholder
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent 13F...
MarketBeat·8d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·9d ago
News Placeholder
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX
TD Asset Management Inc lowered its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 42.7% in the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·15d ago
News Placeholder
What is HC Wainwright's Estimate for MLTX FY2027 Earnings?
MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for MoonLake Immunotherapeutics in a research note issued on...
MarketBeat·18d ago
News Placeholder
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00
Royal Bank Of Canada increased their price objective on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a "sector perform" rating in a report on Monday...
MarketBeat·19d ago
<
1
2
...
>

Latest MLTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.